|

Fazirsiran Injection Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: ADS-001, ARO-AAT, TAK-999, TAK-999, ARO-AAT, ADS-001

Pipeline

Phase 3: 2

Top Sponsors

  • Takeda2

Indications

  • Alpha1-Antitrypsin Deficiency2
  • Liver Disease2

Birmingham, Alabama1 trial

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

University of Alabama at Birmingham

Phase 3

Phoenix, Arizona1 trial

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

St Joseph's Hospital and Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.